David W. Meline - Feb 9, 2022 Form 4 Insider Report for Moderna, Inc. (MRNA)

Role: Chief Financial Officer
Signature: /s/ Brian Sandstrom, as Attorney-in-Fact
Stock symbol: MRNA
Transactions as of: Feb 9, 2022
Transactions value $: -$98,354
Form type: 4
Date filed: 2/11/2022, 03:33 PM
Next filing: Mar 3, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	MRNA	Common Stock	Options Exercise	$0	+1.39K	+86.03%	$0.00	3.01K	Feb 9, 2022	Direct	F1, F2
transaction	MRNA	Common Stock	Sale	-$98.4K	-619	-20.56%	$158.89	2.39K	Feb 10, 2022	Direct	F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	MRNA	Restricted Stock Units	Options Exercise	$0	-1.39K	-24.99%	$0.00	4.18K	Feb 9, 2022	Common Stock	1.39K	$0.00	Direct	F1, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Restricted stock units convert into common stock on a one-for-one basis.
F2	Includes 118 shares acquired under the Moderna, Inc. 2018 Employee Stock Purchase Plan on November 30, 2021.
F3	Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
F4	25% of the shares subject to this restricted stock unit award vested on February 9, 2022 with the remainder vesting in twelve (12) equal quarterly installments thereafter.